152 related items for PubMed ID: 15951468
1. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
Budde K, Lehne G, Winkler M, Renders L, Lison A, Fritsche L, Soulillou JP, Fauchald P, Neumayer HH, Dantal J, RADW 102 Renal Transplant Study Group.
J Clin Pharmacol; 2005 Jul; 45(7):781-91. PubMed ID: 15951468
[Abstract] [Full Text] [Related]
2.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
3. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
Budde K, Neumayer HH, Lehne G, Winkler M, Hauser IA, Lison A, Fritsche L, Soulillou JP, Fauchald P, Dantal J, RADW 102 Renal Transplant Study Group.
Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
[Abstract] [Full Text] [Related]
4. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.
Budde K, Fritsche L, Waiser J, Glander P, Slowinski T, Neumayer HH, RADW 102 Renal Transplant Study Group.
Eur J Med Res; 2005 Apr 20; 10(4):169-74. PubMed ID: 15946913
[Abstract] [Full Text] [Related]
5. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
Transplant Proc; 2006 Sep 20; 38(7):2032-4. PubMed ID: 16979990
[Abstract] [Full Text] [Related]
6. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
J Heart Lung Transplant; 2008 Feb 20; 27(2):197-202. PubMed ID: 18267227
[Abstract] [Full Text] [Related]
7. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
Liver Transpl; 2006 Nov 20; 12(11):1640-8. PubMed ID: 16598777
[Abstract] [Full Text] [Related]
8.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
10. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
Montagnino G, Sandrini S, Iorio B, Schena FP, Carmellini M, Rigotti P, Cossu M, Altieri P, Salvadori M, Stefoni S, Corbetta G, Ponticelli C.
Nephrol Dial Transplant; 2008 Feb 20; 23(2):707-14. PubMed ID: 17890244
[Abstract] [Full Text] [Related]
11. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.
Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD.
Clin Pharmacol Ther; 1998 Jan 20; 63(1):48-53. PubMed ID: 9465841
[Abstract] [Full Text] [Related]
12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
Clin Ther; 2006 Jun 20; 28(6):893-905. PubMed ID: 16860172
[Abstract] [Full Text] [Related]
13. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
Transpl Immunol; 2006 Jun 20; 16(1):46-51. PubMed ID: 16701176
[Abstract] [Full Text] [Related]
14. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
Transpl Int; 2007 Jan 20; 20(1):27-36. PubMed ID: 17181650
[Abstract] [Full Text] [Related]
15. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T, Waiser J, Lichter S, Schumann B, Neumayer HH, Kamar N, Budde K.
Cytokine; 2008 Jun 20; 42(3):306-11. PubMed ID: 18440821
[Abstract] [Full Text] [Related]
16. Everolimus in clinical practice--renal transplantation.
Pascual J.
Nephrol Dial Transplant; 2006 Jul 20; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[Abstract] [Full Text] [Related]
17. Late acute cardiac allograft rejection: new therapeutic options?
Schweiger M, Wasler A, Prenner G, Tripolt M, Schwarz M, Tscheliessnigg KH.
Transplant Proc; 2005 Dec 20; 37(10):4528-31. PubMed ID: 16387161
[Abstract] [Full Text] [Related]
18. Experience with everolimus.
Augustine JJ, Hricik DE.
Transplant Proc; 2004 Mar 20; 36(2 Suppl):500S-503S. PubMed ID: 15041396
[Abstract] [Full Text] [Related]
19. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L.
Transplantation; 2003 Oct 15; 76(7):1079-84. PubMed ID: 14557756
[Abstract] [Full Text] [Related]
20. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, Baraldo M, Franceschi L, Furlanut M, Viale P.
Ann Pharmacother; 2008 Nov 15; 42(11):1711-6. PubMed ID: 18812562
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
